
PODD
Insulet Corporation
Company Overview
| Mkt Cap | $22.50B | Price | $333.48 |
| Volume | 899.66K | Change | +6.58% |
| P/E Ratio | 53.8 | Open | $321.97 |
| Revenue | $2.1B | Prev Close | $312.89 |
| Net Income | $418.3M | 52W Range | $230.05 - $353.50 |
| Div Yield | N/A | Target | $376.17 |
| Overall | 65 | Value | 40 |
| Quality | -- | Technical | 90 |
No chart data available
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News
Insulet (PODD) Gets a Buy from Truist Financial
RBC Capital Remains a Buy on Insulet (PODD)
Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)
Barclays Sticks to Their Hold Rating for Insulet (PODD)
Insulet Appoints Robbie Huffines as New Director
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PODD | $333.48 | +6.6% | 899.66K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |